WHO ICTRP trial
Drug Eluting Scaffold with an absorbable platform for primary lower extremity…
NL-OMON42932 · Overview of Medical Research in the Netherlands (NL-OMON) · Not Recruiting
Key facts
| Trial ID | NL-OMON42932 |
|---|---|
| Public title | Drug Eluting Scaffold with an absorbable platform for primary lower extremity arterial revascularization |
| Scientific title | Drug Eluting Scaffold with an absorbable platform for primary lower extremity arterial revascularization - DESappear |
| Primary sponsor | Elixir Medical Corporation |
| Registry | Overview of Medical Research in the Netherlands (NL-OMON) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Countries | Belgium;Germany;Netherlands ;New Zealand |
| Conditions | peripheral arterial disease /symptomatic primary atherosclerotic stenoses and occlusions of the superficial femoral artery (SFA);10003216;peripheral arterial disease /symptomatic primary atherosclerotic stenoses and occlusions of the… |
| Interventions | treatment of symptomatic primary atherosclerotic stenoses and occlusions of the superficial femoral artery (SFA) ;Drug Eluting Scaffold;lower extrimities;Resorbable |
| Registration date | Mar 1, 2017 |
| Target size | 10 |
| Secondary IDs | NL58385.100.16 |
| Registry page | onderzoekmetmensen.nl |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: